WallStreetZenWallStreetZen

NASDAQ: SNDX
Syndax Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for SNDX

Based on 6 analysts offering 12 month price targets for Syndax Pharmaceuticals Inc.
Min Forecast
$23.00-0.35%
Avg Forecast
$34.50+49.48%
Max Forecast
$42.00+81.98%

Should I buy or sell SNDX stock?

Based on 6 analysts offering ratings for Syndax Pharmaceuticals Inc.
Strong Buy
Strong Buy
4 analysts 66.67%
Buy
1 analysts 16.67%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SNDX stock forecasts and price targets.

SNDX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-28
lockedlocked$00.00+00.00%2024-06-26
lockedlocked$00.00+00.00%2024-06-17
lockedlocked$00.00+00.00%2024-05-21
lockedlocked$00.00+00.00%2024-05-09
ScotiaBank
Top 34%
67
HoldDowngrades$23.00-0.35%2024-01-31

1 of 1

Forecast return on equity

Is SNDX forecast to generate an efficient return?
Company
-13.3%
Industry
71.74%
Market
80.3%
SNDX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SNDX forecast to generate an efficient return on assets?
Company
-12.05%
Industry
30.97%
SNDX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SNDX earnings per share forecast

What is SNDX's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
-$3.49
Avg 2 year Forecast
-$2.89
Avg 3 year Forecast
-$2.19

SNDX revenue forecast

What is SNDX's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$38.5M
Avg 2 year Forecast
$105.1M
Avg 3 year Forecast
$218.2M

SNDX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SNDX$23.08$34.50+49.48%Strong Buy
ARVN$28.52$68.70+140.88%Strong Buy
NVAX$13.85$19.00+37.18%Buy
IMCR$39.78$81.88+105.82%Strong Buy
EWTX$21.36$33.20+55.43%Strong Buy

Syndax Pharmaceuticals Stock Forecast FAQ

Is Syndax Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: SNDX) stock is to Strong Buy SNDX stock.

Out of 6 analysts, 4 (66.67%) are recommending SNDX as a Strong Buy, 1 (16.67%) are recommending SNDX as a Buy, 1 (16.67%) are recommending SNDX as a Hold, 0 (0%) are recommending SNDX as a Sell, and 0 (0%) are recommending SNDX as a Strong Sell.

If you're new to stock investing, here's how to buy Syndax Pharmaceuticals stock.

What is SNDX's earnings growth forecast for 2024-2026?

(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.64%.

Syndax Pharmaceuticals's earnings in 2024 is -$240,634,000.On average, 7 Wall Street analysts forecast SNDX's earnings for 2024 to be -$296,239,395, with the lowest SNDX earnings forecast at -$338,248,499, and the highest SNDX earnings forecast at -$249,861,956. On average, 7 Wall Street analysts forecast SNDX's earnings for 2025 to be -$245,612,603, with the lowest SNDX earnings forecast at -$313,602,251, and the highest SNDX earnings forecast at -$90,936,154.

In 2026, SNDX is forecast to generate -$185,951,687 in earnings, with the lowest earnings forecast at -$228,615,191 and the highest earnings forecast at -$127,480,590.

What is SNDX's revenue growth forecast for 2024-2026?

(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.24%.

Syndax Pharmaceuticals's revenue in 2024 is $0.On average, 5 Wall Street analysts forecast SNDX's revenue for 2024 to be $3,268,942,276, with the lowest SNDX revenue forecast at $560,064,725, and the highest SNDX revenue forecast at $8,583,693,060. On average, 5 Wall Street analysts forecast SNDX's revenue for 2025 to be $8,930,440,265, with the lowest SNDX revenue forecast at $6,280,543,734, and the highest SNDX revenue forecast at $12,323,123,700.

In 2026, SNDX is forecast to generate $18,545,706,259 in revenue, with the lowest revenue forecast at $14,565,932,213 and the highest revenue forecast at $28,275,194,862.

What is SNDX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: SNDX) forecast ROA is -12.05%, which is lower than the forecast US Biotechnology industry average of 30.97%.

What is SNDX's Price Target?

According to 6 Wall Street analysts that have issued a 1 year SNDX price target, the average SNDX price target is $34.50, with the highest SNDX stock price forecast at $42.00 and the lowest SNDX stock price forecast at $23.00.

On average, Wall Street analysts predict that Syndax Pharmaceuticals's share price could reach $34.50 by Jun 28, 2025. The average Syndax Pharmaceuticals stock price prediction forecasts a potential upside of 49.48% from the current SNDX share price of $23.08.

What is SNDX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: SNDX) Syndax Pharmaceuticals's current Earnings Per Share (EPS) is -$3.23. On average, analysts forecast that SNDX's EPS will be -$3.49 for 2024, with the lowest EPS forecast at -$3.98, and the highest EPS forecast at -$2.94. On average, analysts forecast that SNDX's EPS will be -$2.89 for 2025, with the lowest EPS forecast at -$3.69, and the highest EPS forecast at -$1.07. In 2026, SNDX's EPS is forecast to hit -$2.19 (min: -$2.69, max: -$1.50).

What is SNDX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: SNDX) forecast ROE is -13.3%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.